Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2015-07-16 Proxy Solicitation & In…
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2015-07-16 English
PRIMARY DOCUMENT
Director's Dealing
2015-07-14 English
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2015-07-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the announcement of the transfer of listing of the company's stock from OTCQB to NASDAQ Capital Market. This is a regulatory announcement about a change in the company's stock listing venue. The document is not a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the listing transfer event. Therefore, the most appropriate classification is 'Delisting Announcement' (DLST) or a related category. However, since the company is transferring listing to NASDAQ (not delisting from an exchange), the correct category is not DLST. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories. Confidence is high due to the clear nature of the filing as a Form 8-K with a listing transfer announcement.
2015-07-09 English
FORM 8-A
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It includes details about the registrant, the securities to be registered, and signatures. This form is a regulatory filing related to securities registration and does not contain financial statements, earnings data, or management discussion. It is not an annual report, earnings release, or any other financial report type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2015-07-09 English
PRIMARY DOCUMENT
Director's Dealing
2015-07-09 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.